← Back to Search

Anti-tumor antibiotic

Relacorilant, 150mg QD for Fallopian Tube Cancer

Phase 2
Waitlist Available
Research Sponsored by Corcept Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months from enrollment of last subject
Awards & highlights

Summary

This trial is testing a new drug called relacorilant with another drug in patients whose ovarian, fallopian tube, or peritoneal cancer does not respond to standard treatments. Relacorilant may help make the treatment more effective by targeting specific parts of the body. The other drug has been widely used and studied for its effectiveness in treating various cancers, including ovarian cancer.

Eligible Conditions
  • Fallopian Tube Cancer
  • Peritoneal Carcinoma
  • Ovarian Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months from enrollment of last subject
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months from enrollment of last subject for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Progression Free Survival (PFS)
Secondary study objectives
Best Overall Response (BoR)
Best Overall Response in patients who crossover to continuous treatment at time of PD
Cancer Antigen (CA)-125 Response
+9 more

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Intermittent Relacorilant DosingExperimental Treatment2 Interventions
Patients will be treated with relacorilant, administered orally, on the day before (excluding Cycle 1, Day -1), the day of, and the day after nab-paclitaxel, in combination with nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.
Group II: Continuous Relacorilant DosingExperimental Treatment2 Interventions
Patients will be treated with relacorilant, administered orally, once daily every day in combination with nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.
Group III: Nab-paclitaxel ComparatorActive Control1 Intervention
Patients will receive nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.

Find a Location

Who is running the clinical trial?

Corcept TherapeuticsLead Sponsor
69 Previous Clinical Trials
6,305 Total Patients Enrolled
Dorothy Nguyen, MDStudy DirectorCorcept Therapeutics
5 Previous Clinical Trials
395 Total Patients Enrolled
Lyndah Dreiling, MDStudy DirectorCorcept Therapeutics
5 Previous Clinical Trials
755 Total Patients Enrolled
~27 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top